Bone pathologic fracture revealing an unusual association: coexistence of Langerhans cell histiocytosis with Rosai-Dorfman disease
© The Author(s). 2017
Received: 17 December 2016
Accepted: 29 March 2017
Published: 7 April 2017
The coexistence of Rosai-Dorfman disease (RDD) with Langerhans cell histiocytosis (LCH) is very rare, as to date only 17 cases have been reported in the english literature. The pathophysiology of this uncommon co-occurrence still remains enigmatic and a subject of various speculations.
We report a case of a 30-year-old female patient who presented with a pathologic fracture of the left proximal femur. Her medical history was unremarkable, there were no fever, skin lesions, lymphadenopathy or other organomegaly at physical examination. X-ray radiograph of the fractured femur showed an isolated and ill-defined osteolytic lesion. The histopathological analysis of biopsies from this lesion were consistent with a combined RDD-LCH of the bone.
Combined RDD-LCH is a very rare phenomenon, whose pathophysiology still remains unclear and a subject of various speculations.
KeywordsLangerhans cell histiocytosis Rosai-Dorfman disease Pathology
Histiocytic disorders are a are and heterogenous entity comprising a large variety of diseases with a wide spectrum of clinical, histological, molecular and prognostic features [1, 2]. Langerhans cell histiocytosis (LCH) and Rosai-Dorfman disease (RDD) are among the most common component of the large group of histiocytic disorders [1, 3].
Recent studies suggested that LCH is a clonal proliferation of abnormal dendricytic cells (Langerhans cells) with a particular phenotype, CD1a+, S-100+ and CD68+ . The disease can affect one organ or involve several organs or systems, such as skin, bones, lymph nodes, the nervous system, the spleen or the liver [1, 4].
In contrast, RDD is a non-neoplastic disease characterized by a polyclonal proliferation and a tissue accumulation of CD1a- histiocytes [2, 3, 5]. Like LCH, the disease can involve one organ, especially lymph nodes, but extra-nodal sites account for approximately 25–43% of all cases [2, 6]. Most common extranodal sites include the skin, nasal cavity, soft tissue, bones, salivary glands and central nervous system .
However, the co-occurrence of RDD and LCH is a very rare phenomenon. Since the first case of combined RDD-LCH reported in 2002 by Wang KH et al. , to the best of our knowledge, only 16 additionnal cases have been reported in the english literature. We report herein, another additionnal case of this rare association with the particular synchronous occurrence in the bone tissue.
Reported cases of combined RDD-LCH
No. of cases
Wang KH et al. 
Kong YY et al. 
Sachdev R et al. 
O’Malley DP et al. 
2 M/7 F
LN : 8
Abdominal mass/SC : 1
Llamas-Velasco M et al. 
Cohen-Barak. E et al. 
Jin W et al. 
Kutty SA et al. 
Litzner BR et al. 
The morphologic diagnosis often shows typical features of both types of histiocytosis, RDD and LCH [4, 5]. The cells of the LCH component have the classic bean-shaped or coffee-like appearance and grooved or folded nuclei with pink and granular cytoplasm [4, 9]. These cells show no emperipolesis unlike in RDD. Variable amount of inflammatory cells, especially eosinophils are associated with LCH . The immunophenotype is typically CD1a+, CD207+, CD68+, S-100+ [1, 4, 5, 9]. In areas of RDD, the most eye-catching feature is emperipolesis that shows cells with a huge cytoplasm containing intact inflammatory cells like plasma cells, lymphocytes, neutrophils, eosinophils or macrophages [2, 4, 5]. The so-called Rosai-Dorfman cells (RD-cells) have characteristic cytologic features. They are moderate to large in size with abundant, ill-defined and granular cytoplasm; nuclei are round or oval with smooth contours, vesicular and marginated chromatin with unconspicuous round nucleoli [2, 4]. RD-cells are usually surrounded by numerous inflammatory cells, such as lymphocytes, plasma cells, neutrophils and less often eosinophils [2, 4]. At immunochemistry, RD-cells express CD68, CD163, S-100, without expression of CD207 or CD1a . Cells with emperipolesis have typically RD-cells immunophenotype, especially negative for CD1a and langerin (CD207). When combined in the same organ, the RDD component seems to be larger than the LCH component, that presents often as scattered CD1a + cells [4, 7, 13]. This habitual pattern is not seen at immunohistochemistry in our case. In fact, at HES-staining (Hematein-Safran-Eosin), emperipolesis was the first eye-catching appearance in our case (Fig. 2), and typical LCH cells were very rare, seen as scattered cells among the diffuse infiltrate and the accompaning emperipolesis figures (Fig. 2). But, at immunohistochemistry, most mononuclear cells were strongly CD1a positive, only some mononuclear cells and cells with emperipolesis figures were negative for this marker (Fig. 3a). A careful look at CD1a + cells shows that they have mostly a round to oval shape, and often correspond to cells that have RDD appearance at HES-staining (Fig. 3b). These aspects were strongly suggestive of what O’Malley DP et al. called for the first time in their largest series of 9 cases of RDD-LCH, “Banks cells”, an eponym related to one of the co-authors (Peter M Banks) that initially brought these cells to other authors attention . These “Banks cells” were a minor component of lesions (less than 5% of all lesional cells), which had morphologic features comparable to RDD, with larger round nuclei and open chromatin and increased cytoplasm, but with CD1a and Langerin expression. These cells seemed to display transitional features between a lesional cell of LCH and RDD . So, in accordance with these authors, we could say that our current case is a “Banks cells”-riched case of RDD-LCH, or transitional cells-riched case.
Anyway, transitional cells present or not, the main enigmatic and challenging issue is the exact pathological and molecular mechanism underlining the association between RDD and LCH. In fact, previous studies have supported a similar cytokine-mediated mechanisms in both RDD and LCH, and it has been speculated that the RDD presents as a reaction to LCH, or that both LCH and RDD could result from divergent differenciation from a common precursor, or that the histiocytes have undergone a phenotypic switch [1, 4, 5]. LCH is considered as a monoclonal and neoplastic disease as a number of studies showed that, it is usually associated with BRAF mutation [1, 3]. In contrast, RDD is still supposed to be a reactive disease [1, 5]. However, O’Malley DP et al. and Cohen-Barak et al., reported some cytogenetic abnormalities associated to some combined RDD-LCH cases [4, 5]. What is obvious, in some reported RDD-LCH cases, is that the RDD appeared secondarily after initial LCH-RDD  or LCH [5, 12], suggesting that the RDD was a reactive response to LCH. Similar co-existence with juvenile xanthogranuloma (JXG) or secondary “transformation” of LCH to JXG, have been reported [14, 15]. JXG is another subtype of the wide spectrum of histiocytic disorders, its association with LCH, as reported previously [14, 15], was another yet enigmatic issue. Chemotherapy has been evoked as a cause of the secondary apparition of RDD after treatment of the initial LCH .
As suggested by previous authors, the co-existence of RDD and LCH is more than a simple coincidence, and more studies in the future are required to highlight the complex relationship between the two entities.
Association between RDD and LCH is a very rare occurrence; a few cases have been reported in the current literature. The mechanism by which these entities occur together still remains a subject of various speculations, and future studies are required to unveil this enigmatic and challenging fact.
Langerhans cell histiocytosis
The authors received no specific funding for this study.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
BE wrote the article and made substantial contributions to conception and design of the article; AM, BC, GAE, LT, ISS, FE, NH, AE and HEF made critical assessement of the article; LC has been involved in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329–35.View ArticlePubMedGoogle Scholar
- Kroft SH. Rosai-Dorfman disease: familiar yet enigmatic. Semin Diagn Pathol. 2016;33(5):244–53.View ArticlePubMedGoogle Scholar
- Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261–72.View ArticlePubMedGoogle Scholar
- O’Malley DP, Duong A, Barry TS, Chen S, Hibbard MK, Ferry JA, et al. Co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: possible relationship of two histiocytic disorders in rare cases. Mod Pathol. 2010;23(12):1616–23.View ArticlePubMedGoogle Scholar
- Cohen-Barak E, Rozenman D, Schafer J, Krausz J, Dodiuk-Gad R, et al. An unusual co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: report of a case and review of the literature. Int J Dermatol. 2014;53(5):558–63.View ArticlePubMedGoogle Scholar
- Mantilla JG, Goldberg-Stein S, Wang Y. Extranodal Rosai-Dorfman disease: clinicopathologic series of 10 patients with radiologic correlation and review of the literature. Am J Clin Pathol. 2016;145(2):211–21.View ArticlePubMedGoogle Scholar
- Wang KH, Cheng CJ, Hu CH, Lee WR. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol. 2002;147(4):770–4.View ArticlePubMedGoogle Scholar
- Kong YY, Kong JC, Shi DR, Lu HF, Zhu XZ, et al. Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China. Am J Surg Pathol. 2007;31(3):341–50.View ArticlePubMedGoogle Scholar
- Sachdev R, Shyama J. Co-existent Langerhans cell histiocytosis and Rosai-Dorfman disease: a diagnostic rarity. Cytopathology. 2008;19(1):55–8.PubMedGoogle Scholar
- Llamas-Velasco M, Cannata J, Dominguez I, García-Noblejas A, Aragües M, et al. Coexistence of Langerhans cell histiocytosis, Rosai-Dorfman disease and splenic lymphoma with fatal outcome after rapid development of histiocytic sarcoma of the liver. J Cutan Pathol. 2012;39(12):1125–30.View ArticlePubMedGoogle Scholar
- Wei J, Zhang Y, Jin J, Zhang J. Cutaneous Rosai-Dorfman disease accompanied by Langerhans cell hyperplasia responsive to combined treatment. Chin Med J (Engl). 2014;127(17):3200.Google Scholar
- Kutty SA, Sreehari S. Co-occurrence of intracranial Rosai-Dorfman disease and Langerhans histiocytosis of the skull : case report and review of literature. Turk Neurosurg. 2015;25(3):496–9.PubMedGoogle Scholar
- Litzner BR, Subtil A, Vidal CI. Combined cutaneous Rosai-Dorfman disease and localized cutaneous Langerhans cell histiocytosis within a single subcutaneous nodule. Am J Dermatopathol. 2015;37(12):936–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu H, Kong J, Gu Y, Ling B, Xi Z, Yao Z. A child with coexistent juvenile xanthogranuloma and Langerhans cell histiocytosis. J Am Acad Dermatol. 2010;62(2):329–32.View ArticlePubMedGoogle Scholar
- Patrizi A, Neri I, Bianchi F, Guerrini V, Misciali C, et al. Langerhans cell histiocytosis and juvenile xanthogranuloma. Two case reports. Dermatology. 2004;209(1):57–61.View ArticlePubMedGoogle Scholar